Vantage logo

Esketamine floats past adcom vote

Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.


Company Events

Vantage logo

Darzalex's ambitions extend beyond Maia

Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.


Vantage logo

Albireo comes up to IBAT in Nash

Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.

Vantage Homepage